Present and future of target therapies and theranostics: refining traditions and exploring new frontiers-highlights from annals of Nuclear Medicine 2021

Cristiano Pini^{1

2}, Fabrizia Gelardi^{3

4}, Martina Sollini^{1

2}

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4 Pieve Emanuele, 20090, Milan, Italy.
² IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
³ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4 Pieve Emanuele, 20090, Milan, Italy. fabrizia.gelardi@st.hunimed.eu.
⁴ IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy. fabrizia.gelardi@st.hunimed.eu.

Editorial

Cristiano Pini et al. Eur J Nucl Med Mol Imaging. 2022 Sep.

. 2022 Sep;49(11):3613-3621.

doi: 10.1007/s00259-022-05921-7.

Cristiano Pini^{1

2}, Fabrizia Gelardi^{3

4}, Martina Sollini^{1

2}

¹ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4 Pieve Emanuele, 20090, Milan, Italy.
² IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
³ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4 Pieve Emanuele, 20090, Milan, Italy. fabrizia.gelardi@st.hunimed.eu.
⁴ IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy. fabrizia.gelardi@st.hunimed.eu.

No abstract available

References

1. Historical Timeline - SNMMI [Internet]. [cited 2022 Jun 27]. Available from: http://www.snmmi.org/AboutSNMMI/Content.aspx?ItemNumber=4175
1. Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, et al. Theranostics in nuclear medicine practice. Onco Targets Ther. Dove Press; 2017;10:4821
1. Carrió I. New section in EJNMMI and annals of nuclear medicine. Eur J Nucl Med Mol Imaging. 2016;43:2448. - DOI
1. Ledwon A, Paliczka-Cieślik E, Syguła A, Olczyk T, Kropińska A, Kotecka-Blicharz A, et al. Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer. Ann Nucl Med Springer Japan. 2021;35:1214–22. - DOI
1. Özdoğan Ö, Aksu A, Doğan E, Bülbül O, Güray Durak M, Sevinç Aİ, et al. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma. Ann Nucl Med 2021 352. Springer; 2021;35:223–31